Insurance and Access Implications of an Over-the-Counter Switch for a Progestin-Only Pill

Authors

  • By Jennifer McIntosh,

    1. Jennifer McIntosh is visiting researcher at the Department of Pharmacy, Hospital Clínic, Barcelona, Spain
    Search for more papers by this author
  • Britt Wahlin,

    1. Britt Wahlin is director of development and communications, Ibis Reproductive Health, Cambridge, MA
    Search for more papers by this author
  • Kate Grindlay,

    1. Kate Grindlay is senior project manager, Ibis Reproductive Health, Cambridge, MA
    Search for more papers by this author
  • Myra Batchelder,

    1. Myra Batchelder is reproductive health consultant. Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco
    Search for more papers by this author
  • Daniel Grossman

    Corresponding author
    1. Daniel Grossman is vice president for research, Ibis Reproductive Health, and assistant clinical professor, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco
    • Jennifer McIntosh is visiting researcher at the Department of Pharmacy, Hospital Clínic, Barcelona, Spain
    Search for more papers by this author

Author contact: DGrossman@ibisreproductivehealth.org

Ancillary